How to improve communication for the safe use of medicines?: Discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO programme for international drug monitoring

Drug Safety

Volumn 35, Issue 12, 2012, Pages 1073-1079

  Bahri, Priya ^a   Harrison Woolrych, Mira ^b  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Drug monitoring; Health care provider; Meetings; Pharmacovigilance; World Health Organization

Indexed keywords

ARTICLE; COOPERATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE PERSONNEL; HUMAN; PATIENT; PATIENT SAFETY; PRIORITY JOURNAL; RISK REDUCTION; SOCIAL MARKETING; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMMUNICATION; DRUG MONITORING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PATIENT EDUCATION AS TOPIC; PHARMACOVIGILANCE; PHYSICIAN-PATIENT RELATIONS; SOCIAL MARKETING; WORLD HEALTH ORGANIZATION;

EID: 84868627885     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11640530-000000000-00000     Document Type: Article

References (25)

1. The future is now: current concepts in risk management [topical edition]. Drug Saf 2004; 27: 489-617
2. US Food and Drug and Administration. Guidance for industry: development and use of risk minimization action plans. Rockville (MD): Food and Drug Administration, 2005
3. European Medicines Agency. Guideline on risk management systems for medicinal product for human use. London: European Medicines Agency, 2005 (since then revised and included in ref. [4]
4. European Commission. Volume 9A of the Rules Governing Medicinal Products in the European Union: guidelines on pharmacovigilance for medicinal products for human use (revised 2008). Bruxelles: European Commission, 2007
5. US Food and Drug and Administration. Guidance for industry: format and content of proposed risk evaluation and mitigation strategies (REMS), REMS assessments, and proposed REMS modifications [draft]. Silver Spring (MD): Food and Drug Administration, 2009
6. Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring: cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf 1997; Suppl. 3: S71-7 (Pubitemid 27483543)
7. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring: cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; Suppl 3: S79-90 (Pubitemid 27483544)
8. Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross-sectional incidence study. BMJ 2000; 320: 1036 (Pubitemid 30198972)
9. Phillips J, Beam S, Brinker A, et al. Retrospective analysis of mortalities associated with medication errors. Am J Health System Pharm 2001; 58: 1835-41 (Pubitemid 32924234)
10. Beijer HJM, Blaey de CJ. Hospitalisations caused by adverse reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54 (Pubitemid 34534816)
11. Institute of Medicine of the National Academies (IOM). Preventing medication errors. Washington, DC: National Academies Press, 2006
12. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2006; 63: 136-47 (Pubitemid 46072098)
13. Council of Europe Expert Group on Safe Medication Practices. Creation of a better medication safety culture in Europe: building up safe medication practices. Strasbourg: Council of Europe, 2007
14. Leendertse AJ, Egberts ACG, Stoker LJ, et al., for the HARM study group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-6
15. Hakkarainen KM, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions: a meta-analysis. PLOS One 2012; 7: e33236, 1-9
16. World Health Organization. Pharmacovigilance [online]. Available from URL: http://www.who.int/medicines/areas/quality-safety/safety-efficacy/ pharmvigi/en/index.html [Accessed 2011 Aug 11]
17. Furedi A. The public health implications of the 1995 "pill scare". Hum Reprod Update 1999; 5: 621-6 (Pubitemid 30034884)
18. Kotler P, Roberto N, Lee N. Social marketing: improving the quality of life. Thousands Oaks (CA): Sage, 2002
19. World Health Organization. The importance of pharmacovigilance. Geneva: World Health Organization, 2002
20. Pharmaceuticals and Medical Devices Agency. Automobile accidents associated with the use of smoking cessation aid CHAMPIX(varenicline tartrate) [PDMA request for proper use of drugs]. Tokyo: Pharmaceuticals and Medical Devices Agency, 2011 Oct 2 [online]. Available from URL: http://www.pmda.go.jp/ english/service/pdf/request/No2.pdf [Accessed 2012 Jan 24]
21. Medicines and Healthcare products Regulatory Agency. Public consultation (MLX 364): the regulation of nicotine containing products (NCPs). London: Medicines and Healthcare products Regulatory Agency (last modified 9 March 2011) [online]. Available from URL: http://www. mhra.gov.uk/Publications/ Consultations/Medicinesconsul tations/MLXs/CON065617 [Accessed 2012 Jan 24]
22. Kutner M, Greenberg E, Jin Y, et al. The health literacy of American adults: results from the 2003 National Assessment of Adult Literacy. Washington, DC: US Department of Education, 2006
23. World Health Organization. Thirty-third annual meeting of representatives of national centres participating in the WHO Programme for International Drug Monitoring, 1-3 November 2010.WHOPharmaceuticals Newsletter 2010; 6: 8-11
24. World Health Organization. Thirty-fourth annual meeting of representatives of national centres participating in the WHO Programme for International Drug Monitoring 30 October-2 November 2011. WHO Pharmaceuticals Newsletter 2012; 1: 25-7
25. Tadin J, MacolićSarinićV. Communicating safety issues: the Croatian experience. Uppsala Reports 2012; 57: 15